Coronary Artery Disease (CAD)
The purpose of this study is to test the safety of taking aspirin plus 3 months of a second blood thinner (antiplatelet) medicine [such as clopidogrel (Plavix), or prasugrel (Effient), or ticagrelor (Brilinta)] in people who have a SYNERGY stent.
Principal Investigator: Molly Szerlip, MD
Locations: Baylor Scott & White The Heart Hospital – Plano
Sponsor: Boston Scientific Corporation
IRB Number: 016-072
Trial Status: Enrolling
Exclusions: Adults only
Change in Care: Participating may change your care
EVOLVE: A prospective, multicenter, single-arm study designed to assess the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention (PCI) with a SYNERGYTM Everolimus-Eluting Platinum Chromium Coronary Stent.
Get Detailed Information On Clinicaltrials.gov »
Physicians are members of the medical staff at one of Baylor Health Care System's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Health Care System.